Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is pleased to announce its participation in the upcoming Lytham Partners Spring 2023 Investor Conference. The virtual event will take place on Thursday, May 18, 2023 and will provide an opportunity for Reviva, a clinical-stage pharmaceutical company developing therapies to address unmet medical needs in the areas of CNS, respiratory, and metabolic diseases, to connect with potential investors and discuss its progress and plans for the future.
About Reviva’s Lead Drug Candidate Brilaroxazine
Reviva’s breakthrough new chemical entity, brilaroxazine, has demonstrated potent affinity and selectivity against the key serotonin and dopamine receptors that are implicated in schizophrenia and its associated symptoms.
In a multinational, double-blind Phase 2 study with 234 patients with acute schizophrenia or schizoaffective disorder, brilaroxazine met its primary endpoint and showed statistically significant improvement of overall drug treatment outcomes. It was also observed to be safe, with no weight gain, no increase in blood sugar and lipids, and no cardiac or endocrine adverse effects compared to placebo.
As such, the U.S. Food and Drug Administration (FDA) has agreed to consider a potential superior safety label claim if a positive outcome is seen in a pivotal Phase 3 study in patients with schizophrenia. Moreover, Reviva is also looking to develop brilaroxazine for other neuropsychiatric indications such as bipolar disorder, major depressive disorder (MDD) and attention-deficit/hyperactivity disorder (ADHD).
Reviva is developing brilaroxazine, a promising treatment for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). This drug has shown impressive efficacy for mitigating lung fibrosis and inflammation in animal models, and the U.S. FDA has granted it Orphan Drug Designation for these conditions. With this drug, Reviva hopes to delay the progression of PAH and IPF and improve the lives of those affected by these diseases.
Reviva is a clinical-stage biopharmaceutical company that is revolutionizing the world of medicine. By discovering, developing, and commercializing next-generation therapeutics to treat diseases with unmet medical needs, Reviva is improving the lives of patients and their families.
Its current pipeline focuses on the central nervous system, respiratory and metabolic diseases, and includes two drug candidates, brilaroxazine and RP1208, both of which have been granted composition of matter patents in the U.S., Europe, and other countries.